Allogene has taken a step closer to developing a viable off-the-shelf CAR-T therapy, becoming the first to match the durability of established autologous treatments after many years of setbacks and disappointments.
Its updated Phase I data presented at the American Society of Clinical Oncology congress show a complete response rate of...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
